{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:42:10Z","timestamp":1792370530220,"version":"4.4.0"},"reference-count":25,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the clinical validity of Cxbladder Triage Plus (Pacific Edge Ltd., Dunedin, New Zealand), a non\u2010invasive urinary biomarker assay, for urothelial carcinoma (UC) risk stratification compared with standard\u2010of\u2010care evaluation (cystoscopy) in patients presenting with visible or non\u2010visible haematuria (VH or NVH) in routine practice in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A multicentre, prospective, observational study (AUSSIE; Australian and New Zealand Clinical Trial Registry identifier: ACTRN12622001127796) enrolled adults (aged \u226518\u2009years) presenting with VH or NVH, no UC history and a cystoscopy referral between September 2023 and August 2025 across four Australian clinical sites. Midstream urine samples were tested with Cxbladder Triage Plus prior to cystoscopy. The primary outcome was diagnostic performance of Cxbladder Triage Plus (sensitivity, specificity, positive predictive value [PPV], negative PV [NPV], and test\u2010negative rate [TNR]) vs white light cystoscopy and histopathological UC confirmation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 691 patients with evaluable samples (424 with VH, 267 with NVH), 54 (7.8%) had histopathology\u2010confirmed tumours (44 with VH, 10 with NVH). Compared with cystoscopy, Cxbladder Triage Plus had sensitivity of 89%, specificity 79%, PPV 27%, NPV 99%, and TNR 74%. Six tumours were not detected (five low\u2010grade Ta, one T3b urachal adenocarcinoma). Compared with 2025 American Urological Association risk stratification criteria, Cxbladder Triage Plus provided a 3.3\u2010fold increase in PPV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings provide clinical validation of Cxbladder Triage Plus for UC risk stratification in Australian patients presenting with VH or NVH in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.70504","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:28:59Z","timestamp":1792369739000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of Cxbladder Triage Plus in Australian patients with haematuria: the\n                    <scp>AUSSIE<\/scp>\n                    study"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5175-0069","authenticated-orcid":false,"given":"Varun","family":"Buhariwalla","sequence":"first","affiliation":[{"name":"Austin Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Sethi","sequence":"additional","affiliation":[{"name":"Austin Health  Melbourne Victoria Australia"},{"name":"University of Melbourne  Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Vela","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital  Brisbane Queensland Australia"},{"name":"School of Biomedical Science, Faculty of Health Queensland University of Technology  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4094-401X","authenticated-orcid":false,"given":"Dickon","family":"Hayne","sequence":"additional","affiliation":[{"name":"UWA Medical School University of Western Australia  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahrah","family":"Atchia","sequence":"additional","affiliation":[{"name":"Monash Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-2048","authenticated-orcid":false,"given":"Michel","family":"de Lange","sequence":"additional","affiliation":[{"name":"Pacific Edge Ltd  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Lough","sequence":"additional","affiliation":[{"name":"Pacific Edge Ltd  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"White","sequence":"additional","affiliation":[{"name":"Pacific Edge Ltd  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weranja","family":"Ranasinghe","sequence":"additional","affiliation":[{"name":"Monash Health  Melbourne Victoria Australia"},{"name":"Cabrini Research  Melbourne Victoria Australia"},{"name":"Monash Clinical School Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"key":"e_1_2_12_2_1","article-title":"Painless visible haematuria in adults: an algorithmic approach guiding management","volume":"11","author":"Dulku G","year":"2019","journal-title":"Cureus"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/JU.0000000000004490","article-title":"Updates to microhematuria: AUA\/SUFU guideline (2025)","volume":"213","author":"Barocas DA","year":"2025","journal-title":"J Urol"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2022.03.027","article-title":"Systematic review of the incidence of and risk factors for urothelial cancers and renal cell carcinoma among patients with haematuria","volume":"82","author":"Rai BP","year":"2022","journal-title":"Eur Urol"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/jso.28148","article-title":"Evaluating cost\u2010effective strategies for asymptomatic microhematuria diagnosis: a risk\u2010based alternative to the American urological association guidelines","volume":"131","author":"Sridalla K","year":"2025","journal-title":"J Surg Oncol"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1186\/s12879-025-11593-z","article-title":"Effect of antibiotic prophylaxis after flexible cystoscopy to prevent symptomatic urinary tract infection: a randomized controlled trial","volume":"25","author":"Seeluangsawat A","year":"2025","journal-title":"BMC Infect Dis"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.euros.2021.06.014","article-title":"Evaluating the safety of performing flexible cystoscopy when urinalysis suggests presence of \u201cinfection\u201d: results of a prospective clinical study in 2350 patients","volume":"31","author":"Trail M","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"65.e13","DOI":"10.1016\/j.urolonc.2025.10.008","article-title":"Diagnostic performance of Cxbladder triage plus for the identification and stratification of patients at risk for urothelial carcinoma: the multicenter, prospective, observational DRIVE study","volume":"44","author":"Savage SJ","year":"2026","journal-title":"Urol Oncol"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-07-1672","article-title":"Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder","volume":"14","author":"Holyoake A","year":"2008","journal-title":"Clin Cancer Res"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-015-0018-5","article-title":"A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma","volume":"15","author":"Kavalieris L","year":"2015","journal-title":"BMC Urol"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.juro.2012.05.003","article-title":"A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria","volume":"188","author":"O'Sullivan P","year":"2012","journal-title":"J Urol"},{"key":"e_1_2_12_12_1","first-page":"71","article-title":"Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy","volume":"133","author":"Davidson PJ","year":"2020","journal-title":"N Z Med J"},{"key":"e_1_2_12_13_1","first-page":"55","article-title":"Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy","volume":"132","author":"Davidson PJ","year":"2019","journal-title":"N Z Med J"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/UPJ.0000000000000972","article-title":"Real\u2010world utility of Cxbladder triage for patients with microhematuria: a matched cohort study","volume":"13","author":"Filson CP","year":"2026","journal-title":"Urol Pract"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/cas.14000","article-title":"Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell\u2010free DNA in upper tract urothelial carcinoma","volume":"110","author":"Hayashi Y","year":"2019","journal-title":"Cancer Sci"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/JU.0000000000003126","article-title":"Urinary analysis of FGFR3 and TERT gene mutations enhances performance of Cxbladder tests and improves patient risk stratification","volume":"209","author":"Lotan Y","year":"2023","journal-title":"J Urol"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3390\/diagnostics15141739","article-title":"Analytical validation of the Cxbladder\u00ae triage plus assay for risk stratification of hematuria patients for urothelial carcinoma","volume":"15","author":"Harvey JC","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"e_1_2_12_18_1","unstructured":"OpenClinica LLC.OpenClinica version 4.0 software [Internet].2016Available from:https:\/\/www.openclinica.com\/solutions\/electronic\u2010data\u2010capture\u2010edc\/. Cited April 2026."},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1136\/bmj.308.6943.1552","article-title":"Diagnostic tests. 1: sensitivity and specificity","volume":"308","author":"Altman DG","year":"1994","journal-title":"BMJ"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/bmj.309.6947.102","article-title":"Diagnostic tests. 2: predictive values","volume":"309","author":"Altman DG","year":"1994","journal-title":"BMJ"},{"key":"e_1_2_12_21_1","volume-title":"R: A Language and Environment for Statistical Computing [Internet]","author":"R Core Team","year":"2024"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","volume":"351","author":"Bossuyt PM","year":"2015","journal-title":"BMJ"},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Elm E","year":"2007","journal-title":"Lancet"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/JU.0000000000002135","article-title":"The diagnostic performance of Cxbladder resolve, alone and in combination with other Cxbladder tests, in the identification and priority evaluation of patients at risk for urothelial carcinoma","volume":"206","author":"Raman JD","year":"2021","journal-title":"J Urol"},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13148-022-01240-8","article-title":"Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation","volume":"14","author":"Hentschel AE","year":"2022","journal-title":"Clin Epigenetics"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0090-4295(91)80349-C","article-title":"Primary adenocarcinoma of bladder","volume":"38","author":"Wilson TG","year":"1991","journal-title":"Urology"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70504","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70504","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:29:03Z","timestamp":1792369743000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":25,"alternative-id":["10.1111\/bju.70504"],"URL":"https:\/\/doi.org\/10.1111\/bju.70504","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"assertion":[{"value":"2026-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bju.70504"}}